Ubiquitin Modification Patterns of Clear Cell Renal Cell Carcinoma and the Ubiquitin Score to Aid Immunotherapy and Targeted Therapy

Abstract

Ubiquitin modification is the most common protein post-translational modification (PTM) process in organisms, and 1332 ubiquitin regulators have been identified in humans. Ubiquitin regulators, especially E3 ligases and deubiquitinases, are widely involved in immune processes. This study aims to explore the ubiquitin modification features of clear cell renal cell carcinoma (ccRCC) and to elucidate the role of such ubiquitin modifications in shaping anti-tumor immunity and individual benefits from immune checkpoint blockade (ICB). A comprehensive analysis was performed in the TCGA cohort (n = 530) and GEO cohort (n = 682). RNA sequencing data of 758 differentially expressed regulators, which was validated by the proteomics data, was used for k-means unsupervised consensus clustering and three ubiquitin patterns of ccRCC were identified. Then, we focused on the ubiquitin modification and tumor progression signatures, immune infiltration characteristics, and prognostic value. The three patterns with different ubiquitin modification signatures correspond to “immune desert phenotype,” “immune resistance phenotype,” and “immune-inflammatory phenotype,” respectively. To facilitate clinical application, we constructed a ubiquitin score to evaluate individual patients’ ubiquitination outcome, and it was demonstrated to be an independent risk factor for overall survival (OS) in multivariate Cox analysis. It was found that the high score group was correlated to higher immune cells infiltrating level and PD-1/PD-L1/CTLA-4 expression. More importantly, we found that the high score group was predicted to be sensitive to anti-PD-1 treatment, while the low-score group showed lower predicted IC50 values in treatment with Pazopanib and Axitinib. In summary, this study elucidated the potential link between ubiquitin modification and immune infiltration landscape of ccRCC for the first time and provided a new assessment protocol for the precise selection of treatment strategies for patients with advanced ccRCC.

Immune-related gene signature associates with immune landscape and predicts prognosis accurately in patients with Wilms tumour

“…Promisingly, immunotherapy provides a unique opportunity to create novel treatment strategies that could be rapidly implemented in the clinic. Due to the inhomogeneity and interaction of anti-tumour immune responses and cancer biology, one single biomarker was unable to sufficiently predict response to immunotherapy ( 58 , 59 ). A lack of greater understanding of tumour immunology may be an underlying cause of failure for most immunotherapies to date.…”

Comprehensive Analysis of Histone Modifications in Hepatocellular Carcinoma Reveals Different Subtypes and Key Prognostic Models

“…These are the favorable characteristics to maintain the malignant progression of the tumor [ 35 ]. It is speculated that high levels of chemokines and their receptors and immune checkpoints block their anti-tumor immune response, resulting in poor prognosis of this subtype [ 36 ]. Although C3 had the highest expression of immune checkpoint, it should be noted that samples of C3 subtype were resistant to immunotherapy.…”

Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma

“…In order to analyze the expression of immune checkpoints in distinct cohorts, we extracted 15 immune checkpoint molecules (GZMA, LAG3, IDO1, CXCL10, CD274, HAVCR2, IFNG, CD8A, TNF, CTLA4, PRF1, PDCD1, GZMB, TBX2, and CXCL9) according to the study of Peng et al. ( 39 ). Jiang et al.…”